OptiNose’s (NASDAQ:OPTN) lock-up period is set to end on Wednesday, April 11th. OptiNose had issued 7,500,000 shares in its initial public offering on October 13th. The total size of the offering was $120,000,000 based on an initial share price of $16.00. Shares of the company owned by company insiders and major shareholders will be eligible for trade following the expiration of the lock-up period.
OPTN has been the subject of several recent analyst reports. Piper Jaffray set a $28.00 price objective on shares of OptiNose and gave the company a “buy” rating in a report on Monday, January 15th. Zacks Investment Research cut shares of OptiNose from a “hold” rating to a “sell” rating in a report on Saturday, March 17th. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. OptiNose has a consensus rating of “Buy” and a consensus price target of $29.25.
OptiNose stock opened at $19.30 on Friday. The company has a quick ratio of 15.99, a current ratio of 16.13 and a debt-to-equity ratio of 0.47. The company has a market capitalization of $709.98 and a PE ratio of -3.43. OptiNose has a 12-month low of $15.01 and a 12-month high of $25.24.
OptiNose (NASDAQ:OPTN) last posted its quarterly earnings data on Tuesday, March 13th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by ($0.18). sell-side analysts anticipate that OptiNose will post -3 EPS for the current fiscal year.
In other OptiNose news, CEO Peter K. Miller bought 5,054 shares of OptiNose stock in a transaction that occurred on Friday, March 16th. The stock was purchased at an average cost of $18.58 per share, for a total transaction of $93,903.32. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
A number of large investors have recently modified their holdings of the stock. Peregrine Capital Management LLC bought a new stake in OptiNose during the fourth quarter worth approximately $6,314,000. Kornitzer Capital Management Inc. KS bought a new stake in OptiNose during the fourth quarter worth approximately $6,040,000. Driehaus Capital Management LLC bought a new stake in OptiNose during the fourth quarter worth approximately $5,521,000. Wells Fargo & Company MN bought a new stake in OptiNose during the fourth quarter worth approximately $5,392,000. Finally, BlackRock Inc. bought a new stake in OptiNose during the fourth quarter worth approximately $4,351,000. Hedge funds and other institutional investors own 29.49% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “OptiNose Inc’s (OPTN) Lock-Up Period Will End on April 11th” was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another domain, it was stolen and reposted in violation of US & international trademark & copyright laws. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/04/08/optinose-incs-optn-lock-up-period-will-end-on-april-11th.html.
OptiNose Company Profile
OptiNose, Inc is a pharmaceutical company. The Company is focused on the development and commercialization of products for patients treated by ear, nose and throat, or ENT, and allergy specialists. The Company’s products candidates include XHANCE (Nasal Polyps), XHANCE (Chornic Sinusitis) OPN-300, OPN-021, and other.
Receive News & Ratings for OptiNose Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptiNose and related companies with MarketBeat.com's FREE daily email newsletter.